NRG-BR001基准认证结果:首个NCI资助的多发转移立体定向放疗试验
NRG-BR001是首个由美国国家癌症研究所资助、针对2-4个颅外转移灶的立体定向体部放疗试验,要求进行基准认证以确保方案依从性,尤其是近距离转移灶。本文总结基准剂量学结果与批准率:63份基准中94%获批,51%首次获批;多数采用VMAT单计划,PTV覆盖与OAR保护优先选择差异大,部分计划虽满足DVH指标但适形性差而不合格。
要点
- 63份基准中94%获批,51%首次获批;78%用VMAT,90%用单计划治疗双PTV。
- 右侧和左侧PTV的D95中位剂量分别为44.8±1.0 Gy和44.9±1.0 Gy。
- 保护胃的计划显著降低左侧PTV和胃剂量,但PTV覆盖与OAR保护优先选择差异大。
核心结论
- 多数计划采用VMAT,但适形性和剂量跌落范围差异大,优先保护OAR或PTV覆盖的选择差异显著,可能影响试验毒性结局。
- 部分基准满足DVH指标但适形性低而不合格;常见问题文档发布提高了首次获批率,基准认证是教育机构了解方案要求的有效工具。
研究设计与样本
- 使用双侧肾上腺转移(正常组织间隔<5 cm)患者的匿名数据作为基准,PTV与OAR重叠,需按计划优先指南平衡PTV覆盖(45 Gy分3次)与OAR保护。
- 提交计划由成像与放射肿瘤学核心处理,方案联合主席比较靶区、OAR剂量和适形性指标并用非参数检验评估。
主要发现
- 78%使用容积旋转调强放疗(VMAT),90%用单个计划治疗两个PTV,75%优先PTV而非胃。
- 右侧和左侧PTV的D95中位剂量分别为44.8±1.0 Gy和44.9±1.0 Gy。
- 脊髓D0.03 cm³中位剂量为14.2±2.2 Gy,胃D0.03 cm³中位剂量为46.5±3.1 Gy。
- 保护胃的计划显著降低左侧PTV和胃剂量;单计划同时治疗双PTV时适形性指标显著优于分开计划,PTV外2 cm剂量无显著差异。
关键数值与推荐
- PTV覆盖处方为45 Gy分3次。
- 基准病例为双侧肾上腺转移,正常组织间隔<5 cm。
临床怎么用
- 机构应遵循计划优先指南平衡PTV覆盖与OAR保护,并关注适形性指标,避免仅满足DVH但适形性差的计划。
- 推荐使用单计划同时治疗多个PTV以提高适形性,并参考常见问题文档以提高首次获批率。
局限性
- 基准认证结果基于单一双侧肾上腺转移病例,可能不能完全代表其他部位多发转移的规划难度。
- 计划优先选择差异大,但未报告其对临床毒性结局的实际影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The NRG-BR001 trial is the first National Cancer Institute-sponsored trial to treat multiple (range 2-4) extracranial metastases with stereotactic body radiation therapy. Benchmark credentialing is required to ensure adherence to this complex protocol, in particular, for metastases in close proximity. The present report summarizes the dosimetric results and approval rates. METHODS AND MATERIALS: The benchmark used anonymized data from a patient with bilateral adrenal metastases, separated by <5 cm of normal tissue. Because the planning target volume (PTV) overlaps with organs at risk (OARs), institutions must use the planning priority guidelines to balance PTV coverage (45 Gy in 3 fractions) against OAR sparing. Submitted plans were processed by the Imaging and Radiation Oncology Core and assessed by the protocol co-chairs by comparing the doses to targets, OARs, and conformity metrics using nonparametric tests. RESULTS: Of 63 benchmarks submitted through October 2015, 94% were approved, with 51% approved at the first attempt. Most used volumetric arc therapy (VMAT) (78%), a single plan for both PTVs (90%), and prioritized the PTV over the stomach (75%). The median dose to 95% of the volume was 44.8 ± 1.0 Gy and 44.9 ± 1.0 Gy for the right and left PTV, respectively. The median dose to 0.03 cm3 was 14.2 ± 2.2 Gy to the spinal cord and 46.5 ± 3.1 Gy to the stomach. Plans that spared the stomach significantly reduced the dose to the left PTV and stomach. Conformity metrics were significantly better for single plans that simultaneously treated both PTVs with VMAT, intensity modulated radiation therapy, or 3-dimensional conformal radiation therapy compared with separate plans. No significant differences existed in the dose at 2 cm from the PTVs. CONCLUSIONS: Although most plans used VMAT, the range of conformity and dose falloff was large. The decision to prioritize either OARs or PTV coverage varied considerably, suggesting that the toxicity outcomes in the trial could be affected. Several benchmarks met the dose-volume histogram metrics but produced unacceptable plans owing to low conformity. Dissemination of a frequently-asked-questions document improved the approval rate at the first attempt. Benchmark credentialing was found to be a valuable tool for educating institutions about the protocol requirements.
引用
- Al-Hallaq HA, Chmura SJ, Salama JK, et al. Benchmark Credentialing Results for NRG-BR001: The First National Cancer Institute-Sponsored Trial of Stereotactic Body Radiation Therapy for Multiple Metastases. Int J Radiat Oncol Biol Phys. 2016. PMID: 27843033. doi:10.1016/j.ijrobp.2016.09.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。